Streetbeat News

Products Services

ADAG

Adagene Inc. (NASDAQ:ADAG) has announced its poster presentation at the Society for Immunotherapy of Cancer 38th Annual Meeting. The presentation will focus on the optimal dose selection for its masked anti-CTLA-4 SAFEbody ADG126. The data reinforces the mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 12:06 pm

ANVS

Annovis Bio has announced an interim independent analysis for statistical power in its Alzheimer's study. The analysis is expected to provide insights into the effectiveness of the company's ongoing research.

Portfolio Pulse from Bill Haddad

October 12, 2023 | 12:06 pm

VTAK

Catheter Precision's VIVO, a cardiac mapping system, is now eligible for national reimbursement in the U.K. This could potentially increase the product's sales and usage in the country.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 12:05 pm

OCEA

Ocean Biomedical and Virion Therapeutics have entered into a joint venture to accelerate and expand Virion's clinical-stage program and pipeline. Virion has begun enrolling a first-in-humans study, 'VRON-0200,' for chronic Hepatitis B virus infection.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 12:05 pm

INAB

IN8bio, Inc. (NASDAQ:INAB) has completed enrollment in the Phase 1 study of INB-100 in leukemia patients and initiated patient enrollment in the Phase 2 clinical trial evaluating INB-400 in newly diagnosed glioblastoma multiforme (GBM). The company's CEO, William Ho, expressed optimism about the potential of gamma-delta T cells as a treatment option for both solid and hematological cancers. INB-400 was granted Orphan Drug Designation by the FDA in April 2023.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 12:03 pm

NVCR

Novocure has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. This program is intended to support preclinical studies and clinical trials with TTFields.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 12:02 pm

DRCT

Direct Digital Holdings has chosen GreenLake Edge-to-Cloud platform to build a highly reliable, scalable, and secure production environment. The company aims to enhance its operational efficiency and security.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 12:01 pm

DRCT

HPE

Direct Digital Holdings (NASDAQ:DRCT) has chosen Hewlett Packard Enterprise Co's (NYSE:HPE) Greenlake edge-to-cloud platform for building a secure and scalable production environment. The platform will be integrated with Direct Digital's subsidiary, Colossus SSP's infrastructure and cloud services across its marketplace. The marketplace manages around 136,000 clients monthly, generating over 250 billion impressions per month.

Portfolio Pulse from Vandana Singh

October 12, 2023 | 12:00 pm

MTEK

PRZO

Parazero Technologies and Maris-Tech have expanded their collaboration to develop a unified product that integrates safety technology and predictive maintenance for the defense market.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 11:59 am

AZN

FUSN

Fusion Pharmaceuticals (NASDAQ:FUSN) has presented preclinical data for FPI-2068, a targeted alpha therapy for EGFR-cMET expressing cancers. The therapy is being jointly developed with AstraZeneca (NASDAQ:AZN) under a multi-asset collaboration agreement. The data was presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 11:46 am